Literature DB >> 22830357

The over-expression of miR-34a fails to block DoHH2 lymphoma cell proliferation by reducing p53 via c-MYC down-regulation.

Milena Rizzo1, Laura Mariani, Sara Cavallini, Marcella Simili, Giuseppe Rainaldi.   

Abstract

MicroRNAs (miRNAs) might behave as tumor suppressors and for that they are under consideration as novel therapeutic drugs. We tested the tumor suppressor activity of miRNA-34a (miR-34a) by measuring cell proliferation of the follicular lymphoma cell line DoHH2 transfected with this miRNA. We report that miR-34a did not inhibit cell proliferation notwithstanding a marked down-regulation of c-MYC. Interestingly, DoHH2 transfected cells showed a significant p53 down-regulation, suggesting that c-MYC positively controls p53 and the failed inhibition of cell proliferation is probably due to the down-regulation of the c-MYC/p53 axis. In keeping with this, c-MYC silencing also down-regulated p53 and had no effect on cell proliferation. In accordance with this hypothesis, etoposide or nutlin-3 treatment or a small interfering RNA (siRNA) against BCL6 (B-cell lymphoma 6) inhibited the proliferation of DoHH2 cells by up-regulating p53 without affecting either miR-34a or c-MYC levels. These results indicate that the proliferation is controlled by the regulatory axis c-MYC/p53 and suggest that paradoxically miR-34a behaves as a pro-proliferative rather than an anti-proliferative miRNA in DoHH2 cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22830357     DOI: 10.1089/nat.2012.0343

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  8 in total

Review 1.  MicroRNAs in B-cell lymphomas: how a complex biology gets more complex.

Authors:  K Musilova; M Mraz
Journal:  Leukemia       Date:  2014-12-26       Impact factor: 11.528

2.  Altered microRNA expression in folliculotropic and transformed mycosis fungoides.

Authors:  Dóra Marosvári; Vanda Téglási; Irén Csala; Márta Marschalkó; Csaba Bödör; Botond Timár; Judit Csomor; Judit Hársing; Lilla Reiniger
Journal:  Pathol Oncol Res       Date:  2015-02-20       Impact factor: 3.201

3.  Aberrant microRNA expression in tumor mycosis fungoides.

Authors:  E Papadavid; M Braoudaki; M Bourdakou; A Lykoudi; V Nikolaou; G Tounta; A Ekonomidi; E Athanasiadis; G Spyrou; C Antoniou; S Kitsiou-Tzeli; D Rigopoulos; A Kolialexi
Journal:  Tumour Biol       Date:  2016-09-13

Review 4.  MicroRNAs in B-cells: from normal differentiation to treatment of malignancies.

Authors:  Sara Correia Marques; Maria Bach Laursen; Julie Støve Bødker; Malene Krag Kjeldsen; Steffen Falgreen; Alexander Schmitz; Martin Bøgsted; Hans Erik Johnsen; Karen Dybkaer
Journal:  Oncotarget       Date:  2015-01-01

5.  MiR-492 impairs the angiogenic potential of endothelial cells.

Authors:  Francesca Patella; Eleonora Leucci; Monica Evangelista; Brian Parker; Jiayu Wen; Alberto Mercatanti; Milena Rizzo; Elena Chiavacci; Anders H Lund; Giuseppe Rainaldi
Journal:  J Cell Mol Med       Date:  2013-06-26       Impact factor: 5.310

6.  Regulation of aryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas.

Authors:  Judit Dénes; Leandro Kasuki; Giampaolo Trivellin; Leandro M Colli; Christina M Takiya; Craig E Stiles; Sayka Barry; Margaret de Castro; Mônica R Gadelha; Márta Korbonits
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

7.  cMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas.

Authors:  Valentina Manfè; Edyta Biskup; Ayalah Willumsgaard; Anne Guldhammer Skov; Dario Palmieri; Pierluigi Gasparini; Alessandro Laganá; Anders Woetmann; Niels Ødum; Carlo Maria Croce; Robert Gniadecki
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

Review 8.  Competitive Endogenous RNA Network Involving miRNA and lncRNA in Non-Hodgkin Lymphoma: Current Advances and Clinical Perspectives.

Authors:  Mara Fernandes; Herlander Marques; Ana Luísa Teixeira; Rui Medeiros
Journal:  Biomedicines       Date:  2021-12-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.